Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

Journal of the National Cancer Institute

Volumn 103, Issue 4, 2011, Pages 352-353

  Nielsen, Kirsten Vang ^a   Brünner, Nils ^b  

^a AGILENT TECHNOLOGIES   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; GENE; GENE AMPLIFICATION; GENE DELETION; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOPOISOMERASE II ALPHA GENE;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79951880133     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq528     Document Type: Letter

References (7)

1. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(9):615-618.
2. Oakman C, Moretti E, Sotiriou C, et al. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(24):1735-1736; author reply 1736-1737.
3. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23(30):7483-7490. (Pubitemid 46291811)
4. Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008;47(4):725-734. (Pubitemid 351878451)
5. Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst. 2009;101(9):615-618.
6. Harris LN, Broadwater G, Abu-Khalaf M, et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009;27(21):3430-3436.
7. Tubbs R, Barlow WE, Budd GT, et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009;27(24):3881-3886.